• Profile
Close

Remdesivir to be administered on medical prescription to severe COVID-19 patients

PTI May 03, 2021

Antiviral drug Remdesivir is to be administered only after a medical prescription and limited to severe condition of COVID-19 patients strictly as per medical protocol, the Centre told the Supreme Court on 30 April.

For our comprehensive coverage and latest updates on COVID-19 click here.


A bench headed by Justice D Y Chandrachud was informed that there is a growing demand from some quarters to permit the use of Remdesivir even when a person is taking treatment at his own home under his own private medical supervision. "The argument in support of this demand is to the effect that permitting Remdesivir would lessen the stress upon hospitals and a patient can take treatment from his private physician at home. This argument, at first blush, appears to be an attractive argument.

"More particularly when Remdesivir is to be administered only upon a medical prescription and by a qualified doctor attending to the patient at his residence...the use of Remdevisir must remain limited to severe condition COVID-19 patients strictly as per medical protocol", the Centre told the government in its affidavit. It said that Remdesivir is listed as investigational therapy in the National Clinical Management Protocol: COVID-19 which is prepared by a team of eminent experts of the various fields. As per the Clinical Management Protocol of COVID-19 prepared by a team of eminent experts in the field, it is only moderate to severe cases in which administration of Remdesivir can be considered that too depending upon the clinical judgment of the treating doctor which, in turn, would depend upon several health parameters of each patient, Centre said.

It said that to keep a check on the pricing of the drug the National Pharmaceutical Pricing Authority, on April 17, 2021, released the revised maximum retail price (MRP) for 100mg/Vial of Remdesivir, as communicated by the licensed manufacturers, bringing down the cost of all the major brands to below Rs 3,500 per vial to ensure affordability of the injection among the masses.

The bench, also comprising Justices L Nageswara Rao and S Ravindra Bhat, on April 22 took note of the pandemic situation due to sudden surge in COVID-19 cases as also in mortality and said it expected the Centre to come out with a national plan to deal with the distribution of essential services and supplies, including oxygen and drugs.

Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay